(Reuters) -Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker's $8.5 billion bid for the U.S. obesity drug developer to be a superior offer. Pfizer asked the Delaware court where it filed the lawsuit to issue a temporary restraining order to block Metsera from terminating the agreement. The lawsuit was not immediately available in the court's electronic filing system. Metsera has given ...

(Reuters) -Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, which has been called into question by Novo Nordisk's higher $8.5 billion offer. Metsera has declared Novo's offer superior, and given Pfizer until Tuesday to raise its bid. The U.S. Federal Trade Commission granted early termination of the waiting period required under the Hart-Scott-Rodino Act, which governs antitrust reviews. The waiting period was originally set to e ...

Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal. ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera. Pfizer alleges that the Novo Nordisk offer cannot qualify as a "Superior Company Proposal†u. ...

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. (NASDAQ:MTSR) jumped to a new 52-week high of $66.10 before trimming gains to end the day just up by 22.06 percent at $63.73 apiece. This fo ...

中新网上海10月31日电 (记者 陈静)过去数年来，中国国际进口博览会见证了中国医疗创新生态的蓬勃 活力。第八届进博会即将开幕。爱德华生命科学(简称：爱德华)日本及亚太地区全球副总裁韦恩·马科维 茨( Wayne Markowitz)31日对记者表示，进博会是全球创新成果进入中国市场的重要平台，更是爱德华 深化本土布局、携手共赢的核心纽带。借助进博会这一国家级开放平台，爱德华将引入更多全球前沿创 新成果，并推动其向临床价值的加速转化，让更多患者从中受益。 在本届进博会上，诺和诺德打造了首个聚焦肥胖症健康管理的沉浸式体验空间——"轻盈小屋"。体验者 可通过AI视觉识别互动技术在屏幕中看见"变胖的自己"，结合相应的科普知识及健康风险提示，唤醒公 众对肥胖症的重视；"科学治疗"部分包括医院与零售两大场景，旨在展示"院店协同"新模式，助力打通 肥胖症院内外管理闭环，提升肥胖症管理的便利性、科学性与依从性。 本届进博会上，"司美格鲁肽家族"多款明星产品将携新进展亮相。诺和盈®(全球首个用于长期体重管理 的GLP-1RA周制剂)中国说明书纳入心血管获益结果；诺和泰®(司美格鲁肽注射液)获批新增慢性肾脏病 (CKD)适应证 ...

Eli Lilly dealt a George Foreman-worthy blow in its ongoing heavyweight title bout against Novo Nordisk for weight-loss drugmaker supremacy. The Indianapolis-based pharmaceutical company posted what many analysts pointed to as the strongest earnings of the season on Wednesday. Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring, leaving its weight loss rival’s prospects looking like wishful shrinking. SUBSCRIBE:  Receive more of our free The Daily Upside newsletter. READ ALSO: Chipotle ...

Core Insights - Novo Nordisk has informed employees about job cuts across most of its locations, with the pace of notifications varying based on local laws [1] Group 1 - The company is undergoing significant workforce reductions as part of its restructuring efforts [1] - CEO Mike Doustdar communicated the changes through a post, indicating a strategic shift within the organization [1] - The job cuts are part of a broader trend in the pharmaceutical industry, reflecting ongoing adjustments to market conditions [1]

Core Viewpoint - Pfizer may leverage its connections within the Trump administration to counter Novo Nordisk's unexpected bid for Metsera, a U.S. biotech firm focused on obesity treatments [1] Company Analysis - Pfizer is positioned to utilize political connections to influence the outcome of the acquisition bid [1] - Novo Nordisk's bid for Metsera represents a strategic move in the competitive obesity treatment market [1] Industry Context - The obesity treatment sector is experiencing increased M&A activity, highlighting the competitive landscape among pharmaceutical companies [1] - The involvement of political connections in corporate acquisitions underscores the intersection of healthcare and government policy [1]

Market Overview - US stock markets experienced a decline, with the Dow Jones down 0.23%, Nasdaq down 1.58%, and S&P 500 down 0.99%. Notable movements included Google rising over 2%, Apple slightly up, Nvidia down over 2%, Microsoft down nearly 3%, Amazon down over 3%, Tesla down over 4%, and META down over 11% [1] Company Developments - Intel is reportedly in preliminary talks to acquire AI startup SambaNova Systems Inc. [4] - Nvidia plans to invest up to $1 billion in AI startup Poolside to strengthen its ecosystem [5] - OpenAI announced plans to launch the "Stargate" data center in 2026, with a planned capacity exceeding 8 gigawatts and an investment of over $450 billion in the next three years [6] - Novo Nordisk is set to bid $9 billion for Metsera, challenging an established deal with Pfizer [7] - Merck's Q3 revenue exceeded expectations, driven by strong sales of its COVID-19 vaccine Capvaxive [8] - Meta is seeking to raise at least $25 billion through a large bond issuance [9] - Tesla's $1 trillion compensation plan for Elon Musk faced opposition from significant shareholders [10] Domestic Policy and Market Trends - The US has decided to suspend its 301 investigation measures against China's maritime, logistics, and shipbuilding industries for one year, along with suspending the 50% export control rule announced on September 29 and canceling the 10% "fentanyl tariff" [11] - The National Bureau of Statistics encourages the exploration of cutting-edge technologies and innovation scenarios based on data infrastructure [12] - The Ministry of Finance and other departments are expanding the categories of duty-free shops to support both outbound and inbound duty-free sales [13] Sector Insights - Semiconductor Sector: The China Securities Regulatory Commission approved the IPO application of Moore Threads, a company with a founding team that has Nvidia backgrounds, indicating a shift of domestic computing power from "laboratory" to "capital market" [15] - Financial Technology: The People's Bank of China plans to implement "AI+" initiatives to accelerate the digital and intelligent transformation of finance, with the domestic fintech market expected to exceed 580 billion yuan by 2027, growing at a compound annual growth rate of approximately 12% [16] - Duty-Free Retail: New policies are set to enhance the duty-free shopping experience and promote the sale of domestic products in duty-free shops, which is expected to attract more foreign consumers [17] Company Earnings - Zhongji Xuchuang reported a Q3 net profit of 3.137 billion yuan, a year-on-year increase of 124.98% [22] - Demingli's Q3 net profit reached 90.87 million yuan, up 166.80% year-on-year [22] - Tuojing Technology's Q3 net profit was 462 million yuan, reflecting a 225.07% increase year-on-year [22] - Silan Microelectronics reported a Q3 net profit of 84.27 million yuan, up 56.62% year-on-year [22] - Gree Electric's Q3 net profit was 7.049 billion yuan, a decline of 9.92% year-on-year [22]